UroGen Pharma (URGN) Stock Analysis & AI Equity Report

Biotechnology USD Explore free reports

UroGen Pharma (URGN) overview

UroGen Pharma (URGN) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 110m and operating profit of USD -125m; the year-end share price was 23.42 USD and market capitalisation was USD 1,132m. UroGen Pharma is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get UroGen Pharma's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.

Key metrics & valuation multiples

Book valueUSD -105mFY 2025
Share price23.42 USDFY 2025 year end
RevenueUSD 110mFY 2025
Operating profitUSD -125mFY 2025
Net earningsUSD -153mFY 2025
Market capitalisationUSD 1,132mFY 2025 year end

About UroGen Pharma

UroGen Pharma develops and commercializes treatments for urothelial and specialty cancers. Its approved products, Jelmyto and Zusduri, combine mitomycin with its RTGel sustained-release hydrogel for local delivery in the upper urinary tract or bladder. Jelmyto is used to treat low-grade upper tract urothelial cancer, while Zusduri treats recurrent low-grade intermediate-risk non-muscle-invasive bladder cancer. The company also has an investigational oncolytic virus in its pipeline.

Generate the UroGen Pharma report

UroGen Pharma is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.

Generate fresh report — €50.00 Delivered by email, usually within an hour

Sources & methodology

Financial figures are sourced from Valuatum's financial model for UroGen Pharma and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.

Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.

Analyst reports on UroGen Pharma

Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.